# BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform
Canonical URL: https://biopharmsignal.com/news/OPKO/bioreferencer-launches-bioreference-directtm-expanding-access-to-consumer-initiated-diagnostic-testing-through-a-fully-integrated-digital-platform
Ticker: OPKO
Company: Opko
Source: Opko
Published: 2026-04-30 12:00 EST
Original Source URL: https://www.opko.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-05-12 12:00 EST — [OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies](https://biopharmsignal.com/news/OPKO/opko-health-s-modex-therapeutics-will-present-data-demonstrating-in-vivo-car-t-cell-generation-and-deep-b-cell-depletion-in-preclinical-studies) — Source: Opko
- 2026-04-30 12:00 EST — [BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform](https://biopharmsignal.com/news/OPKO/bioreferencer-launches-bioreference-directtm-expanding-access-to-consumer-initiated-diagnostic-testing-through-a-fully-integrated-digital-platform) — Source: Opko
- 2026-04-08 12:00 EST — [OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19](https://biopharmsignal.com/news/OPKO/opko-health-s-modex-therapeutics-initiates-clinical-trial-of-mdx2301-for-the-prevention-of-covid-19) — Source: Opko
- 2026-02-27 13:00 EST — [OPKO Health to Participate in the Jefferies Biotech on the Beach Summit](https://biopharmsignal.com/news/OPKO/opko-health-to-participate-in-the-jefferies-biotech-on-the-beach-summit) — Source: Opko
- 2026-02-26 21:05 EST — [OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results](https://biopharmsignal.com/news/OPKO/opko-health-reports-fourth-quarter-2025-business-highlights-and-financial-results) — Source: Opko
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)